Martinez-Raga J.,CEU Cardenal Herrera University |
Gonzalez Saiz F.,Fundacion Andaluza Para la Atencion e Incorporacion Social |
Pascual C.,Hospital Infanta Leonor |
Casado M.A.,Pharmacoeconomics and Outcomes Research Iberia |
Sabater Torres F.J.,Schering
European Addiction Research | Year: 2010
Objective: To evaluate the economic impact of buprenorphine/naloxone (B/N) as an agonist opioid treatment for opiate dependence. Methods: A budgetary impact analysis model was designed to calculate the annual costs (drugs and associated costs) to the Spanish National Healthcare System of methadone versus B/N. Data for the model were obtained from official databases and expert panel opinion. Results: It was estimated that 86,017 patients would be in an agonist opioid treatment program each of the 3 years of the study. No increase in the number of patients is expected with the introduction of B/N combination. The budgetary impact (drugs and associated costs) for agonist opiate treatment in the first year of the study would be 89.53 million EUR. In the first year of B/N use, the budgetary impact would rise by 4.39 million EUR (4.6% of the total impact), with an incremental cost of 0.79 million EUR (0.9% of the total impact). The budgetary increase would be 0.6% (0.48 million EUR increase) and 0.6% (0.49 million EUR increase) in the second and third years of use, respectively. The mean cost per patient in the first year with and without B/N would be EUR 1,050 and 1,041, respectively. The most influential variables in the sensitivity analysis were logistics and production costs of methadone and the percentage use of B/N. Conclusion: With an additional cost of only EUR 9 per patient, B/N is an efficient addition to the therapeutic arsenal in the drug treatment of opiate dependence, particularly when considering clinical aspects of novel pharmacotherapy. © 2009 S. Karger AG, Basel.
Rodriguez-Novoa S.,Hospital Carlos III |
Labarga P.,Hospital Carlos III |
D'Avolio A.,University of Turin |
Barreiro P.,Hospital Carlos III |
And 7 more authors.
AIDS | Year: 2010
Tenofovir (TFV) is a nucleotide analogue active against HIV and hepatitis B virus. Although TFV rarely affects the glomerular function, abnormalities in the kidney tubular function appear to be quite common. The relationship between TFV exposure and kidney tubular dysfunction (KTD) was examined prospectively in 92 HIV-infected individuals. Median TFV plasma trough concentration was higher in patients with KTD than in the rest (182 vs. 106 ng/ml; P = 0.001). This dose-dependent effect further supports an involvement of TFV in KTD. Copyright © 2010 Lippincott Williams & Wilkins.
Estudio secuence clinical and therapeutic evaluation of patients with moderate to severe psoriasis in Spain: The secuence study [Evaluación clínica y terapéutica de los pacientes con psoriasis moderada o grave en España]
Hernanz J.M.,Hospital Infanta Leonor |
Sanchez-Regana M.,Hospital Universitari Sagrat Cor |
Izu R.,Hospital de Basurto |
Mendiola V.,Hospital Virgen de la Victoria |
Actas Dermo-Sifiliograficas | Year: 2012
Background: Evaluation of disease severity is considered essential in the optimal management of psoriasis. Objectives: To describe the clinical characteristics and therapeutic profile of patients with moderate to severe psoriasis in Spain and to assess the impact of the disease on the patients' quality of life. Materials and methods: This was an observational, cross-sectional study carried out in 90 dermatology units in Spain in 2009. We included 442 patients diagnosed with moderate to severe psoriasis who had started treatment with systemic agents, phototherapy, and/or topical treatments between 2004 and 2006. Results: More severe psoriasis was significantly associated with the following: longer disease duration; higher prevalence of concomitant disease; greater involvement of the nails, scalp, flexures, palms, and soles; and poorer quality of life. In the 5 years before the start of the study, 68% of the patients had received conventional systemic treatments, 39.1% biologic agents, and 22.3% phototherapy. At present, 57.5% of the patients are being treated with biologic agents, 32.6% with conventional systemic treatments, and 11% with phototherapy. Conclusions: Severity of psoriasis was associated with a marked impact on quality of life. Regardless of disease severity, psychiatric comorbidity was the strongest predictor of poor quality of life. On average, patients had received other treatments, such as conventional systemic treatments or phototherapy, for more than 2 years before switching to biologic agents for the first time. © 2011 Elsevier España, S.L. and AEDV. All rights reserved.
Brito-Zeron P.,Institute dinvestigacions Biomediques August Pi i Sunyer IDIBAPS |
Retamozo S.,Institute dinvestigacions Biomediques August Pi i Sunyer IDIBAPS |
Gandia M.,University of Cadiz |
Akasbi M.,Hospital Infanta Leonor |
And 8 more authors.
Journal of Autoimmunity | Year: 2012
Objective: To analyze the monoclonal expression of SS through the detection of serum monoclonal immunoglobulins (mIgs) in a large series of patients with Sjögren syndrome (SS), focusing on the etiology, characterization and evolution of the monoclonal band and the association with SS clinical expression and outcomes. Methods: Serum immunoelectrophoresis (IE) was performed to 408 consecutive patients who were evaluated by our unit between 1992 and 2011: 221 patients who fulfilled the 2002 American-European criteria for primary SS, 122 primary SS patients who fulfilled exclusively the 1993 European criteria and 65 patients with SS-associated hepatitis C virus infection. IE was performed at diagnosis and every year during the follow-up. Results: Of the 221 patients with primary SS, 48 (22%) had monoclonal gammopathy. In the control groups, the prevalence was 16% in patients with SS who fulfilled the 1993 criteria (p > 0.05) and 52% in SS-HCV patients (p < 0.001). Monoclonal bands were characterized in 47/48 patients with primary SS: IgG (n = 21), IgM (n = 16), IgA (n = 5) and free light chains (n = 5); the light chain was κ in 28 patients and λ in 19 (κ:λ ratio 1.5). Primary SS patients with monoclonal gammopathy had a higher prevalence of parotidomegaly (38% vs 20%, p = 0.021), vasculitis (21% vs 6%, p = 0.003), neurological involvement (42% vs 23%, p = 0.016), higher mean values of circulating gammaglobulins (23.4 vs 20.6%, p = 0.026), ESR (56.6 vs 37.6 mm/h, p = 0.003), a higher prevalence of RF (69% vs 50%, p = 0.022), low C3 levels (24% vs 11%, p = 0.028), low C4 levels (24% vs 7%, p = 0.003), low CH50 activity (28% vs 11%, p = 0.008) and cryoglobulins (23% vs 8%, p = 0.012) compared with those without monoclonal gammopathy. Of the 48 patients with primary SS and monoclonal gammopathy, 8 developed hematologic neoplasia after a mean follow-up of 10 years, a higher prevalence than observed in patients without monoclonal gammopathy (17% vs 5%, p = 0.009). Survival rates according to the presence or absence of monoclonal gammopathy were 83% and 97%, respectively (log rank 0.004). Conclusion: Monoclonal gammopathy was detected in 22% of patients with primary SS fulfilling the 2002 criteria, with mIgGκ being the most frequent type of band detected. In HCV-associated SS patients, the prevalence was higher (52%) with IgMκ being the most prevalent band detected. Monoclonal gammopathy was associated with a higher prevalence of parotid enlargement, extraglandular features, hypergammaglobulinemia, cryoglobulinemia and related markers (rheumatoid factor, hypocomplementemia), and with a poor prognosis (development of neoplasia and death). © 2012 Elsevier Ltd.
Marin-Pena O.,Hospital Infanta Leonor
Femoroacetabular Impingement | Year: 2012
This book is the first monograph to examine all aspects of femoroacetabular impingement (FAI), an important disease first described early in the twenty-first century. Comprising 27 chapters and including many color illustrations, the book contains a variety of points of view from more than 50 experts from 11 countries and represents an up-to-date compilation of professional knowledge on FAI. The full range of available surgical treatments is carefully described and evaluated, including arthroscopic treatment, the open and mini-open approaches, periacetabular osteotomy, hip resurfacing arthroplasty, and combined techniques. Differential diagnosis, imaging, postoperative management, and treatment outcome are also discussed in appropriate detail. It is hoped that this book will promote a comprehensive approach to what is a common pathology and thereby encourage further improvement in treatment. © 2012 Springer-Verlag Berlin Heidelberg. All rights are reserved.